We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

17 hedge funds and large institutions have $544K invested in Scinai Immunotherapeutics in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

42% more funds holding

Funds holding: 12 → 17 (+5)

0.07% less ownership

Funds ownership: 1.82% → 1.75% (-0.07%)

31% less capital invested

Capital invested by funds: $789K → $544K (-$245K)

Holders
17
Holders Change
+5
Holders Change %
+41.67%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
3
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$81.3K
2
Citadel Advisors
Citadel Advisors
Florida
+$61K
3
Millennium Management
Millennium Management
New York
+$29K
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$7.26K
5
Morgan Stanley
Morgan Stanley
New York
+$5.81K

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$200K
2
ECM
ExodusPoint Capital Management
New York
-$74K
3
TSS
Two Sigma Securities
New York
-$37.7K
4
JP Morgan Chase
JP Morgan Chase
New York
-$1K

SCNI Hedge Fund Activity: Q1 2022 in Review

17 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q1 2022, worth a combined $544K — down 31% from $789K a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new SCNI positions and 2 closed out — a net gain of 6 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $81.3K. The largest seller was State Street, exiting entirely with an estimated $200K sold.

  • 17 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q1 2022, up from 12 in Q4 2021.
  • Funds reported $544K of Scinai Immunotherapeutics stock for Q1 2022, down 31% quarter-over-quarter.
  • 8 funds opened new Scinai Immunotherapeutics positions in Q1 2022 and 2 closed out, a net change of +6 holders.
  • The largest Scinai Immunotherapeutics buyer in Q1 2022 was Susquehanna International Group, an estimated $81.3K added.
  • The largest Scinai Immunotherapeutics seller in Q1 2022 was State Street, an estimated $200K sold.

Based on aggregated 13F filings for Q1 2022.